Search research articles
Contact Us
Filters
Showing results (111-120 of 144) with videos related to
Page
of 15
Sort By:
Annals of Internal Medicine
|
December 21, 2006
Agalsidase-beta therapy for advanced Fabry disease: a randomized trial
Maryam Banikazemi, Jan Bultas, Stephen Waldek, et al.
Pituitary
|
November 5, 2022
Changing the name of diabetes insipidus
Hiroshi Arima, Daniel G Bichet, Timothy Cheetham, et al.
International Journal of Molecular Sciences
|
August 29, 2020
Diurnal Variation of Urinary Fabry Disease Biomarkers during Enzyme Replacement Therapy Cycles
Michel Boutin, Pamela Lavoie, Iskren Menkovic, et al.
Bioanalysis
|
October 17, 2023
Fabry disease biomarkers in patients switched from enzyme-replacement therapy to migalastat oral chaperone therapy
Christiane Auray-Blais, Pamela Lavoie, Tristan Martineau, et al.
Molecular Genetics and Metabolism
|
November 21, 2007
Urinary globotriaosylceramide excretion correlates with the genotype in children and adults with Fabry disease
Christiane Auray-Blais, Denis Cyr, Aimé Ntwari, et al.
Kidney International Reports
|
May 14, 2023
OVERTURE: A Worldwide, Prospective, Observational Study of Disease Characteristics in Patients With ADPKD
Ronald D Perrone, Dorothee Oberdhan, John Ouyang, et al.
American Journal of Medical Genetics. Part A
|
March 29, 2019
Safety of switching to Migalastat from enzyme replacement therapy in Fabry disease: Experience from the Phase 3 ATTRACT study
Derralynn A Hughes, Kathleen Nicholls, Gere Sunder-Plassmann, et al.
The Journal of Clinical Investigation
|
June 16, 2026
GLUT9b- and ABCG2-mediated collecting duct urate transport uncover a vasopressin-independent mechanism of renal water reabsorption
Mohamad Hadla, Jean Marc Mardirossian, Daniel G Bichet, et al.
Journal of Medical Genetics
|
December 21, 2022
Long-term multisystemic efficacy of migalastat on Fabry-associated clinical events, including renal, cardiac and cerebrovascular outcomes
Derralynn A Hughes, Daniel G Bichet, Roberto Giugliani, et al.
Journal of the American Society of Nephrology : JASN
|
May 23, 2000
Report of 33 novel AVPR2 mutations and analysis of 117 families with X-linked nephrogenic diabetes insipidus
Marie-Françoise Arthus, Michèle Lonergan, M Joyce Crumley, et al.
Page
of 15
Search research articles
Search
Showing results (111-120 of 144) with videos related to
Sort By:
Page
of 15
Annals of Internal Medicine
|
December 21, 2006
Agalsidase-beta therapy for advanced Fabry disease: a randomized trial
Maryam Banikazemi, Jan Bultas, Stephen Waldek, et al.
Pituitary
|
November 5, 2022
Changing the name of diabetes insipidus
Hiroshi Arima, Daniel G Bichet, Timothy Cheetham, et al.
International Journal of Molecular Sciences
|
August 29, 2020
Diurnal Variation of Urinary Fabry Disease Biomarkers during Enzyme Replacement Therapy Cycles
Michel Boutin, Pamela Lavoie, Iskren Menkovic, et al.
Bioanalysis
|
October 17, 2023
Fabry disease biomarkers in patients switched from enzyme-replacement therapy to migalastat oral chaperone therapy
Christiane Auray-Blais, Pamela Lavoie, Tristan Martineau, et al.
Molecular Genetics and Metabolism
|
November 21, 2007
Urinary globotriaosylceramide excretion correlates with the genotype in children and adults with Fabry disease
Christiane Auray-Blais, Denis Cyr, Aimé Ntwari, et al.
Kidney International Reports
|
May 14, 2023
OVERTURE: A Worldwide, Prospective, Observational Study of Disease Characteristics in Patients With ADPKD
Ronald D Perrone, Dorothee Oberdhan, John Ouyang, et al.
American Journal of Medical Genetics. Part A
|
March 29, 2019
Safety of switching to Migalastat from enzyme replacement therapy in Fabry disease: Experience from the Phase 3 ATTRACT study
Derralynn A Hughes, Kathleen Nicholls, Gere Sunder-Plassmann, et al.
The Journal of Clinical Investigation
|
June 16, 2026
GLUT9b- and ABCG2-mediated collecting duct urate transport uncover a vasopressin-independent mechanism of renal water reabsorption
Mohamad Hadla, Jean Marc Mardirossian, Daniel G Bichet, et al.
Journal of Medical Genetics
|
December 21, 2022
Long-term multisystemic efficacy of migalastat on Fabry-associated clinical events, including renal, cardiac and cerebrovascular outcomes
Derralynn A Hughes, Daniel G Bichet, Roberto Giugliani, et al.
Journal of the American Society of Nephrology : JASN
|
May 23, 2000
Report of 33 novel AVPR2 mutations and analysis of 117 families with X-linked nephrogenic diabetes insipidus
Marie-Françoise Arthus, Michèle Lonergan, M Joyce Crumley, et al.
Page
of 15